Evaluating the Measurement Properties of a New Instrument-the Migraine Physical Function Impact Diary (MPFID)

Objective: To evaluate the measurement properties of the Migraine Physical Function Impact Diary (MPFID). Background: Guidelines for the management of migraine emphasize the importance of information about the impact of migraine on functioning. The MPFID was developed with input from migraine patients, for assessing the impact of migraine on physical functioning. Design/Methods: Interim data from an observational study among subjects with a history of ≥4 migraine days/month receiving standard migraine care was analyzed. Migraine symptoms and impacts were collected daily for one month using an electronic diary. Patient Global Impression of Change (PGIC), PROMIS Physical Function-Short Form (PROMIS-PF), Headache Impact Test™ (HIT-6™), and Migraine-Specific Quality of Life Questionnaire (MSQ) were completed. Analyses included item analysis/reduction, exploratory factor analysis (EFA), and evaluating reliability (internal consistency, test-retest) and validity (convergent, known-groups). Results: The sample included 342 subjects (mean age=40.1 years, SD=11.7; 87.2% female). Item-level analyses informed dropping 4 of 17 items. EFA indicated two domains: Impact on Everyday Activities (EA) and Physical Impairment (PI). Daily domain scores ranging from 0–100 (higher score=greater impact) are averaged across a month. Both domains exhibited high reliability (EA: α=0.96; PI: α=0.92). Test-retest reliability (among stable subjects based on PGIC) was acceptable (intra-class correlation range, EA: 0.75–0.82; PI: 0.77–0.86). Moderate correlations (all p Conclusions: Findings supported two distinct MPFID domains with excellent reliability and construct validity for assessing impacts of migraine on physical functioning. Disclosure: Dr. Kawata has received personal compensation for activities with Evidera as an employee. Dr. Hsieh has received personal compensation for activities with Evidera as an employee. Dr. Hareendran has received personal compensation for activities with Evidera as an employee. Dr. Bender has received personal compensation for activities with Evidera as an employee. Dr. Shaffer has received personal compensation for activities with Amgen as a consultant. Dr. Sapra has received personal compensation for activities with Amgen as an employee. Se. Sapra holds stock and/or stock options in Amgen. Dr. Desai has received personal compensation for activities with Amgen Inc. as an employee. Dr. Desai hold stock and/or stock options in Amgen Inc. Dr. Widnell has received personal compensation for activities with Amgen as an employee. Dr. Bayliss has received personal compensation for activities with Optum as an employee. Dr. Buse has received personal compensation for activities with Allergan and Lilly as an advisory board member. Dr. Revicki has received personal compensation for activities with Amgen, Abbvie, Johnson u0026 Johnson, BMS, Palatin and Novartis as a consultant and from Evidera as an employee. Dr. Revicki has received personal compensation in an editorial capacity from Journal of Patient Reported Outcomes. Dr. Revicki has received research support from Amgen, Abbvie, Daichi, Palatin and BMS.